TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 24.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,212 shares of the biopharmaceutical company’s stock after purchasing an additional 5,169 shares during the period. Victory Capital Management Inc.’s holdings in TG Therapeutics were worth $466,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Principal Financial Group Inc. boosted its stake in shares of TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 1,322 shares in the last quarter. Swiss National Bank boosted its position in shares of TG Therapeutics by 0.5% during the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,500 shares in the last quarter. nVerses Capital LLC grew its stake in shares of TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the period. Pingora Partners LLC purchased a new position in shares of TG Therapeutics in the 4th quarter valued at about $27,000. Finally, ProShare Advisors LLC lifted its stake in shares of TG Therapeutics by 8.5% in the first quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 1,961 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TGTX. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Stock Down 2.5 %

TGTX stock opened at $24.65 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. TG Therapeutics, Inc. has a 12 month low of $6.46 and a 12 month high of $26.41. The firm has a market capitalization of $3.81 billion, a PE ratio of 107.17 and a beta of 2.21. The company’s 50 day simple moving average is $22.08 and its 200-day simple moving average is $18.35.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) earnings per share. Equities analysts expect that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.